牛磺熊去氧胆酸改善COL4A3突变所致肾损伤
研究构建携带Col4a3 p.G799R突变的转基因Alport综合征小鼠模型,发现突变导致IV型胶原α3链在内质网异常蓄积、分泌缺陷并持续激活内质网应激,经MyD88/p38 MAPK通路引发炎症与凋亡。牛磺熊去氧胆酸作为内质网应激抑制剂可抑制该通路并显著改善小鼠肾功能。
要点
- Col4a3 p.G799R突变致IV型胶原α3α4α5异三聚体减少、α3链内质网蓄积
- 内质网应激经MyD88/p38 MAPK通路介导炎症与凋亡
- 牛磺熊去氧胆酸抑制内质网应激并改善模型小鼠肾功能
核心结论
- COL4A3突变通过内质网应激及MyD88/p38 MAPK通路导致肾损伤,牛磺熊去氧胆酸可能对Alport综合征早期临床治疗有用。
研究设计与样本
- 构建携带Col4a3 p.G799R突变的转基因Alport综合征小鼠模型,该突变此前在一个大型Alport综合征家系中被发现,并结合体内外实验与RNA-seq分析。
主要发现
- 突变导致细胞内及分泌的IV型胶原α3α4α5异三聚体病理性减少。
- 突变IV型胶原α3链在内质网异常蓄积、分泌缺陷,体内外持续内质网应激。
- RNA-seq显示MyD88/p38 MAPK通路介导后续炎症与凋亡信号激活。
- 牛磺熊去氧胆酸抑制内质网应激、促进α3链分泌、抑制MyD88/p38 MAPK通路激活。
- 牛磺熊去氧胆酸治疗显著改善小鼠肾功能。
临床怎么用
- 提示牛磺熊去氧胆酸可能用于Alport综合征的早期临床治疗,尤其针对肾小球损伤。
局限性
- 结果为动物模型与体外实验,尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COL4A3/A4/A5 mutations have been identified as critical causes of Alport syndrome and other genetic chronic kidney diseases. However, the underlying pathogenesis remains unclear, and specific treatments are lacking. Here, we constructed a transgenic Alport syndrome mouse model by generating a mutation (Col4a3 p.G799R) identified previously from one large Alport syndrome family into mice. We observed that the mutation caused a pathological decrease in intracellular and secreted collagen IV α3α4α5 heterotrimers. The mutant collagen IV α3 chains abnormally accumulated in the endoplasmic reticulum and exhibited defective secretion, leading to persistent endoplasmic reticulum stress in vivo and in vitro. RNA-seq analysis revealed that the MyD88/p38 MAPK pathway plays key roles in mediating subsequent inflammation and apoptosis signaling activation. Treatment with tauroursodeoxycholic acid, a chemical chaperone drug that functions as an endoplasmic reticulum stress inhibitor, effectively suppressed endoplasmic reticulum stress, promoted secretion of the α3 chains, and inhibited the activation of the MyD88/p38 MAPK pathway. Tauroursodeoxycholic acid treatment significantly improved kidney function in vivo. These results partly clarified the pathogenesis of kidney injuries associated with Alport syndrome, especially in glomeruli, and suggested that tauroursodeoxycholic acid might be useful for the early clinical treatment of Alport syndrome.
引用
- Yu S, Gu X, Zheng Q, et al. Tauroursodeoxycholic acid ameliorates renal injury induced by COL4A3 mutation. Kidney Int. 2024. PMID: 38782199. doi:10.1016/j.kint.2024.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。